Introduction {#S1}
============

Military personnel are often exposed to stressful conditions and erratic sleep schedules during deployment, thereby increasing their risk of developing a sleep disorder, most notably insomnia ([@B1], [@B2]). Deployment also increases the risk for psychiatric morbidity, including symptoms of posttraumatic stress disorder (PTSD) and depression, which are often comorbid with insomnia ([@B1], [@B3]--[@B5]). Insomnia is the most common symptom for referral in military personnel returning from deployment in Operation Enduring Freedom and Operation Iraqi Freedom ([@B3]). Not only is insomnia common but it also results in substantial costs to the individual and society. In the United States, total costs in productivity loss for chronic insomnia (e.g., employment disruption, insomnia-related accidents) are estimated to be between \$77 and \$92 million each year ([@B6]) and total annual costs are estimated to be beyond \$100 billion ([@B7]). In addition, more than half of military personnel with sleep disturbances present with at least one other medical comorbidity, and those with insomnia are two times more likely to have PTSD ([@B8]). Therefore, there is a complex interplay between sleep quality and maintenance of physical and psychiatric health in military personnel, which likely has underlying biological foundations.

Recent studies have begun to determine the relationship of sleep to psychiatric morbidity in those who are under extreme stress ([@B9]). For example, pre-deployment sleep disturbance is linked to the onset of depression and PTSD following deployment ([@B10]). PTSD includes the symptom of nightmares, which is highly related to insomnia onset and non-remittance ([@B11]). Depression also includes symptoms of insomnia including difficulty falling or staying asleep, and these sleep disturbances often do not remit with standard of care treatment for depression ([@B12]). Therefore, current studies suggest that there is a shared vulnerability among PTSD, depression, and insomnia, and that these symptoms are often highly related in military personnel who deploy. Seeking care for sleep is often less stigmatizing than mental health care, resulting in military personnel seeking care for insomnia at almost five times the rate as mental health care ([@B13], [@B14]). Therefore, a better understanding of the underlying shared vulnerability of PTSD, depression and insomnia symptoms following deployment may inform interventions to address these comorbidities.

Sleep disturbance, PTSD, and depression are all associated with higher concentrations of inflammatory bio-markers, as well as a greater risk for inflammatory-related morbidities including: metabolic syndrome, cardiovascular disease, obesity, and type II diabetes ([@B15]--[@B17]). Even short-term reductions in sleep duration in healthy participants increases inflammatory cytokine production, including interleukin-6 (IL-6) ([@B18]--[@B20]). Chronic insomnia ([@B21]), as well as PTSD and depression are associated with increased concentrations of inflammatory cytokines ([@B22]). We previously reported that PTSD, depression, and insomnia in military personnel are associated with higher concentrations of inflammatory proteins including C-reactive protein (CRP) ([@B23]), and that improved sleep resulted in reductions in inflammation ([@B24]). Although these findings support the relationship between sleep and inflammation, the underlying molecular mechanisms of changes in inflammation following sleep improvement remain elusive ([@B2]). Gene-expression changes lead to differential protein activity in general; however, there are many other mechanisms that can contribute to the regulation of protein production, and availability, including epigenetic modifications. Therefore, gene-expression changes are one of the first investigations that can explain molecular mechanisms related to proteomic activity changes, and provide novel insights into complex inter-relationships among gene-regulatory mechanisms.

Examination of gene-expression profiles provides insight into how altered gene-activity relates to stress exposure and symptoms. Expression of a gene can increase or decrease and is the initial step to producing proteins that communicate cell function changes, including those active in the immune response system. Combat-related stressors, such as irregular work schedules, traumatic brain injuries, and other life threatening events, are linked to greater concentrations of inflammatory proteins, which are likely a result of gene-expression changes ([@B25]). Peripheral blood gene expression is comparable to post-mortem expression in more than 60% of genes, providing a minimally invasive method to investigate gene expression changes in living individuals ([@B26], [@B27]). Peripheral blood has been used to determine that reductions in the expression of circadian rhythm genes, including Clock, brain and muscle Arnt-like protein 1, and Period1, are implicated in symptoms of depression ([@B28]). PTSD is also linked to altered gene expression, including reductions in the expression of immune-regulating genes ([@B29]); however, the role of sleep and depression were not determined. Identification of inflammatory gene-expression changes related to sleep disturbance might allow for an understanding of the impact of insomnia on other systems and may inform development of targeted interventions to help prevent the development of comorbid disorders and inflammation.

To investigate this critical issue, we used an observational study of military personnel following deployment to determine global gene-expression changes related to improved sleep following 3 months of standard of care treatment. These findings may provide the insight needed to understand relationships between sleep, gene regulation of inflammation, and mental health.

Materials and Methods {#S2}
=====================

Study design {#S2-1}
------------

This investigation is part of a large ongoing study of U.S. military personnel attending for an initial evaluation of sleep disturbance at the Madigan Army Medical Center Sleep Medicine Clinic in Tacoma, WA, USA. The institutional review board at Madigan Army Medical Center approved the study, and informed consent was obtained from each participant ([@B5]). Sixty-eight participants met the study's inclusion criteria for a sleep diagnosis and completed both pre- and post-treatment assessments; they are included in this analysis. Study participants who met the inclusion criteria were active-duty military personnel who deployed within the previous 18 months with a current diagnosis of insomnia or comorbid insomnia with obstructive sleep apnea (OSA), as previously described ([@B5]). Participants were excluded from the study if they had a recent history of drug or alcohol abuse or current diagnosis of bipolar disorder, schizophrenia, or other psychotic disorder. Symptoms related to sleep quality, depression, and PTSD were evaluated through validated instruments at pre-treatment and post-treatment. Participants were classified into one of two groups (improved sleep or non-improved sleep) based on changes in sleep quality from pre- to post-treatment. Both groups were compared on gene-expression changes in inflammatory genes, as well as changes in symptoms of PTSD and depression.

Assessment and treatment of insomnia and OSA {#S2-2}
--------------------------------------------

All participants underwent a clinical evaluation and overnight polysomnography as part of a sleep medicine evaluation using standardized techniques previously reported ([@B5]). Depending on their sleep disorder diagnosis, patients were then assigned to a standard of care treatment group. Those with an insomnia diagnosis received 3 months of sleep-focused cognitive behavioral treatment for insomnia (CBT-i), which included aspects of cognitive therapy, stimulus control, sleep restriction, sleep practice (hygiene) education, and time monitoring behavior. Participants diagnosed with comorbid insomnia and OSA received either sleep education or 3 months of CBT-i for their insomnia, and autotitrating positive airway pressure therapy (APAP) for their OSA. A psychologist certified in behavioral sleep medicine or a sleep medicine physician with expertise in CBT-I administered and oversaw all treatments.

Defining improved sleep {#S2-3}
-----------------------

The Pittsburgh sleep quality index (PSQI) was administered to assess participants' sleep quality and sleep dysfunction over the previous month. This self-report questionnaire has strong diagnostic sensitivity in differentiating good and poor sleepers. Based on a scale of 0 (healthy sleep quality) to 21 (unhealthy sleep quality), a cut-off score of more than 5 is consistent with an insomnia diagnosis ([@B30]) and is both reliable (Cronbach's α = 0.83) and valid (κ = 0.75, *p* \< 0.001). For analysis purposes, participants with a reduction in their PSQI score from pre- to post-treatment were assigned to the improved sleep group (*n* = 46). Meanwhile, participants with an increase or no change in PSQI score from pre- to post-treatment were assigned to the non-improved sleep group (*n* = 22).

Assessment of PTSD and depression {#S2-4}
---------------------------------

Symptoms of depression were measured using the quick inventory of depressive symptomatology (QIDS). This 16-item inventory has a total possible score range from 0 (lowest severity) to 27 (highest severity). A score of 11, which indicates a moderate severity of depression, was used as the diagnosis cut-off ([@B31]). The PTSD checklist-military version (PCL-M) was used to determine symptoms of PTSD ([@B32]). A total possible score ranges from 17 (lowest severity) to 85 (highest severity). A total score of 50 and above resulted in a positive PTSD diagnostic screen. The PCL is both reliable and valid compared to the gold standard of the Structured Clinical Interview for DSM-III-R ([@B33]).

mRNA acquisition, quantitation, and hybridization {#S2-5}
-------------------------------------------------

Blood samples were collected in PAXgene blood RNA tubes and processed with PAXgene™ Blood RNA Kits (PreAnalytiX, Qiagen) for RNA extraction. Quality and quantity of extracted RNA were evaluated with the NanoDrop DN-1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA) and the Agilent Bioanalyzer 2100 eukaryotic total RNA Nano assay (Agilent Technologies, Inc., Santa Clara, CA, USA). The 260/280 ratio ranged from 2.03 to 2.34 and the RNA integrity numbers (RIN) were \>7.0 in all samples. According to standards ([@B34]) a RIN of 6.0 or greater is indicative of admissible quality, and no samples were excluded based on this criterion. Using the GeneChip (GC) 3′ IVT Plus Expression kit, each RNA (100 ng) sample was reverse transcribed, converted to biotinylated cRNA, and hybridized to Affymetrix HG-U133 Plus 2.0 microarrays (Affymetrix, Santa Clara, CA, USA), which contain 54,675 probe-sets representing more than 38,500 specific genes. After staining with streptavidin-phycoerythrin and thorough washing, the raw data were obtained by laser scanning imaging. All assays were undertaken based on standard Affymetrix protocols.

Statistical analysis {#S2-6}
--------------------

Partek Genomics Suite software, version 6.6 (Partek Inc., St. Louis, MO, USA), was used for all analytic procedures performed on microarray data. Interrogating probes were imported, and corrections for background signal were applied using the robust multi-array average (RMA) method, with additional corrections applied for the GC-content of probes. The probe-sets were standardized using quantile normalization, and expression levels of each probe underwent log-2 transformation to yield distributions of data that more closely approximated normality.

Parameters for identifying differentially expressed genes over time were then identified using analysis of variance (ANOVA) of each probe set's expression level as a function of time: pre-treatment compared to post-treatment while adjusting for batch effect. A repeated measures comparison was made in each group. Restricted maximum likelihood (REML) method was employed to fit the fixed and random effects of the design separately. Significant differentially expressed gene lists were generated based on criteria of 1.5-fold (up or down) change magnitude and a *p*-value corrected for multiple comparisons using a false discovery rate (FDR) \<0.05, for each group.

Two-tailed chi-square tests and independent *t*-tests were used to investigate any pre-treatment group differences that might affect the main analysis. Fisher's exact tests were used when expected cell counts were \<5. The main analysis investigated the relationship between sleep quality improvements or declines and symptoms of PTSD and depression, and gene expression changes following 3 months of sleep treatment. Separate paired *t*-tests were used to examine changes in outcome variables from pre- to post-treatment for both groups. Independent *t*-tests were used to examine between-group differences on outcome variables. The confidence level was set at *p* = 0.05 for all analyses.

QIAGEN's Ingenuity Pathway Analysis (IPA, QIAGEN Redwood City, [www.qiagen.com/ingenuity](www.qiagen.com/ingenuity)) was used to determine which diseases and disorders related to observed gene-expression changes, as well as top-gene networks implicated in these gene-expression changes.

Results {#S3}
=======

Demographics and clinical characteristics {#S3-7}
-----------------------------------------

The demographic, military, and clinical characteristics of the 68 participants are described in Table [1](#T1){ref-type="table"}. As a whole, the sample was primarily male (97%) and Caucasian (62%) with a mean age of 33.8 years (7.8 SD) and 13.8 years (1.8 SD) of education. At pre-treatment, 47% of participants scored positive for depression and 28% scored positive for PTSD. Current use of relevant medications was reported by 40% of the participants. They include antidepressants (28%), pain medications (18%), benzodiazepines (6%), non-benzodiazepines (6%), and the alpha-blocker, prazosin (4%). At pre-treatment, all participants reported a score of at least six on the PSQI, which is a valid indication of poor sleep. There were no between-group differences in demographic variables \[i.e., age, gender, race, education, body mass index (BMI), medication use, and military characteristics\] with the exception of military rank, for which higher level ranks were more prevalent in the improved sleep group (*p* = 0.015). The prevalence of insomnia, OSA, traumatic brain injury (TBI), depression, and PTSD diagnoses were comparable between groups at baseline and both groups were characterized with high rates of these comorbid symptoms. There was no difference in treatment assignment, either CBT or APAP, between the improved sleep and non-improved sleep groups. The mean score in the PSQI was significantly different, with the improved sleep group having a mean score change of −4.8, whereas the non-improved group had an increase of 2.8 on the PSQI, *p* \< 0.01 (see Table [2](#T2){ref-type="table"}).

###### 

**Demographic, military, and clinical characteristics**.

                                           Improved sleep (*n* = 46)   Non-improved sleep (*n* = 22)   *x*^2^*/t*   *p*
  ---------------------------------------- --------------------------- ------------------------------- ------------ -------
  Age: mean (SD)                           33.5 (7.5)                  34.3 (8.7)                      0.358        0.722
  Males: *n* (%)                           45 (97.8)                   21 (95.5)                       0.293        0.546
  Race: *n* (%)                                                                                        3.663        0.056
   Caucasian                               32 (69.6)                   10 (45.5)                                    
   All others                              14 (30.4)                   12 (54.5)                                    
  Education in years: mean (SD)            14.0 (2.1)                  13.4 (1.3)                      −1.202       0.234
  Rank: *n* (%)                                                                                        5.921        0.015
   Lower                                   26 (56.5)                   19 (86.4)                                    
   Senior or Officer                       20 (43.5)                   3 (13.6)                                     
  Front line military exposure: *n* (%)    17 (37.0)                   9 (40.9)                        0.098        0.754
  Number of deployments: *n* (%)                                                                       0.718        0.397
   1 or 2                                  30 (65.2)                   12 (54.5)                                    
   3 or more                               16 (34.8)                   10 (45.5)                                    
  Time since deployment: *n* (%)                                                                       0.729        0.393
   \<6 months                              14 (30.4)                   9 (40.9)                                     
   \>6 months                              32 (69.6)                   13 (59.1)                                    
  BMI: mean (SD)                           30.2 (4.3)                  30.5 (3.4)                      0.330        0.743
  Medication use: *n* (%)                  16 (34.8)                   11 (50.0)                       1.440        0.230
  OSA diagnosis: *n* (%)                   12 (26.1)                   5 (22.7)                        0.090        0.765
  TBI diagnosis: *n* (%)                   18 (39.1)                   9 (40.9)                        0.020        0.888
  Probable depression diagnosis: *n* (%)   21 (45.7)                   11 (50.0)                       0.113        0.737
  Probable PTSD diagnosis: *n* (%)         11 (23.9)                   8 (36.4)                        1.146        0.284

*BMI, body mass index; OSA, obstructive sleep apnea; PTSD, posttraumatic stress disorder; TBI, traumatic brain injury*.

*Fisher's exact test was used when expected cell counts were \<5*.

###### 

**Pre- and post-treatment symptom severity mean (SD)**.

                        Improved sleep (*n* = 46)   Non-improved sleep (*n* = 22)   Between-group                                                     
  --------------------- --------------------------- ------------------------------- --------------- ------------- ------------- ------------- ------- -------------
  Sleep quality         12.8 (4.1)                  8.0 (3.9)                       **\<0.001**     12.1 (3.6)    14.9 (3.1)    **\<0.001**   0.484   **\<0.001**
  Depression severity   10.5 (5.3)                  8.1 (5.0)                       **0.001**       11.00 (4.7)   12.2 (5.0)    0.134         0.732   **0.002**
  PTSD severity         38.7 (15.3)                 35.6 (16.5)                     0.067           43.5 (16.2)   46.5 (17.6)   0.223         0.237   **0.040**

*^a^Pre- to post-treatment change-score. Bold font indicates findings with significant change*.

Psychological symptom change {#S3-8}
----------------------------

Sleep quality, depression, and PTSD outcomes were assessed before and after 3 months of sleep treatment. Table [2](#T2){ref-type="table"} details the pre- and post-treatment symptom severity of both groups. Briefly, from pre- to post-treatment, the improved sleep group reported significant reductions in depression \[*t*(45) = 3.463, *p* = 0.001\] and a trend for decreases in posttraumatic symptoms \[*t*(45) = 1.875, *p* = 0.067\]. These improvements were significant between groups (all *p*-values \<0.05). Meanwhile, the non-improved sleep group reported no significant change in depression (*p* = 0.134) or posttraumatic symptoms (*p* = 0.223).

Gene-expression profiles {#S3-9}
------------------------

The microarray data revealed that 217 coding genes (Table [3](#T3){ref-type="table"}) were differentially expressed at the follow-up-period compared to baseline in the participants who improved in sleep. Of these 217 genes, 113 genes were down-regulated (Table [4](#T4){ref-type="table"}) and 104 were up-regulated (Table [5](#T5){ref-type="table"}). None of these genes changed significantly in the non-improved sleep group.

###### 

**All differentially expressed genes**.

  Gene symbol                     Gene title                                                                                    Fold-change   *p*-Value
  ------------------------------- --------------------------------------------------------------------------------------------- ------------- -------------
  CCL4                            Chemokine (C---C motif) ligand 4                                                              −3.38991      0.000400502
  EGR3                            Early growth response 3                                                                       −3.33259      4.37E-05
  IL1B                            Interleukin 1, beta                                                                           −3.19348      0.00054254
  TIGIT                           T cell immunoreceptor with Ig and ITIM domains                                                −2.999421     0.000116146
  CD96                            CD96 molecule                                                                                 −2.9992104    0.000593266
  CCL3///CCL3L1///CCL3L3          Chemokine (C---C motif) ligand 3///chemokine (C---C motif) ligand 3-like 1///chemokine        −2.99786      1.32E-05
  CCL5                            Chemokine (C---C motif) ligand 5                                                              −2.96621      0.000882838
  TNF                             Tumor necrosis factor                                                                         −2.90578      0.000536776
  DUSP1                           Dual specificity phosphatase 1                                                                −2.89657      1.73E-05
  GATA3                           GATA binding protein 3                                                                        −2.889336     0.000852941
  PTGS2                           Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)         −2.86159      0.000116328
  BZRAP1                          Benzodiazepine receptor (peripheral) associated protein 1                                     −2.84583      0.000429033
  KIR3DL1///KIR3DL2///LOC727787   Killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1///k         −2.79571      0.00111701
  IL18R1                          Interleukin 18 receptor 1                                                                     −2.79239      0.00131446
  NFATC2                          Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2                     −2.77617      0.000468791
  IFITM1                          Interferon Interferon-induced transmembrane protein 1 (9---27)                                −2.67642      0.000796847
  IL6                             Interleukin 6 (interferon, beta 2)                                                            −2.66587      0.000169597
  IFITM1                          Interferon Interferon-induced transmembrane protein 1 (9---27)                                −2.59115      0.00120357
  GLCCI1                          Glucocorticoid Glucocorticoid-induced transcript 1                                            −2.57928      0.000863656
  PER1                            Period homolog 1 (*Drosophila*)                                                               −2.34547      0.000172781
  TARP///TRGC2                    TCR gamma alternate reading frame protein///T cell receptor gamma constant 2                  −2.31319      0.000858636
  TARP                            TCR gamma alternate reading frame protein                                                     −2.2425       0.00123683
  TP53INP2                        Tumor protein p53 inducible nuclear protein 2                                                 −2.23152      2.18E-04
  CDC14A                          CDC14 cell division cycle 14 homolog A (*S. cerevisiae*)                                      −2.22332      0.00055414
  ZNF831                          Zinc finger protein 831                                                                       −2.21191      0.000940436
  BCL10                           B-cell CLL/lymphoma 10                                                                        −2.19636      1.92E-04
  TARP///TRGC2                    TCR gamma alternate reading frame protein///T cell receptor gamma constant 2                  −2.18635      0.00138229
  TARP///TRGC2                    TCR gamma alternate reading frame protein///T cell receptor gamma constant 2                  −2.17218      0.00136634
  STAT3                           Signal transducer and activator of transcription 3 (acute-phase response factor)              −2.17143      2.79E-05
  IL13                            Interleukin 13                                                                                −2.0998       0.000453301
  ZNF831                          Zinc finger protein 831                                                                       −2.07393      0.000998177
  GZMB                            Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1)                  −2.07291      0.000106599
  KLF12                           Kruppel-like factor 12                                                                        −2.06742      0.000474026
  SPON2                           Spondin 2, extracellular matrix protein                                                       −2.06256      0.000562071
  MBNL2                           Muscleblind-like 2 (*Drosophila*)                                                             −2.06215      0.000146908
  KRAS                            v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog                                          −2.04976      0.000826814
  CRA                             Complement factor C4                                                                          −2.04778987   7.09143E-05
  FCAR                            Fc fragment of IgA, receptor for                                                              −2.03608      1.89E-04
  NCL                             Nucleolin                                                                                     −2.0312       4.39101E-07
  IFRD1                           Interferon-related developmental regulator 1                                                  −2.02534      7.16E-06
  S1PR5                           Sphingosine-1-phosphate receptor 5                                                            −1.99987      0.000877998
  NAP1L5                          Nucleosome assembly protein 1-like 5                                                          −1.9825       0.00103436
  FGFBP2                          Fibroblast growth factor binding protein 2                                                    −1.95856      0.00097833
  TRD@                            T cell receptor delta locus                                                                   −1.95283      0.00111344
  PYHIN1                          Pyrin and HIN domain family, member 1                                                         −1.93462      0.000986752
  GFI1                            Growth factor independent 1 transcription repressor                                           −1.93194      0.00076425
  GZMM                            Granzyme M (lymphocyte met-ase 1)                                                             −1.93125      0.00085383
  TRD@                            T cell receptor delta locus                                                                   −1.9207       0.00111727
  TSC22D3                         TSC22 domain family, member 3                                                                 −1.91096      2.28E-06
  KLRB1                           Killer cell lectin-like receptor subfamily B, member 1                                        −1.90964      0.00136588
  IL18RAP                         Interleukin 18 receptor accessory protein                                                     −1.90962      0.000221487
  ICOS                            Inducible co-stimulator                                                                       −1.903002     0.000880293
  MYLIP                           Myosin regulatory light chain interacting protein                                             −1.89332      8.32E-06
  TGFBR3                          Transforming growth factor, beta receptor III                                                 −1.8931       0.00121075
  ZAP70                           Zeta-chain (TCR) associated protein kinase 70 kDa                                             −1.89061      0.000662326
  CTSW                            Cathepsin W                                                                                   −1.88397      0.00129928
  CEP78                           Centrosomal protein 78 kDa                                                                    −1.88364      0.000127057
  ARL4C                           ADP-ribosylation factor-like 4C                                                               −1.8832       0.000160201
  ARL4C                           ADP-ribosylation factor-like 4C                                                               −1.87226      0.000419378
  KLRD1                           Killer cell lectin-like receptor subfamily D, member 1                                        −1.86593      0.00124982
  PRKCQ                           Protein kinase C, theta                                                                       −1.86552      0.00113571
  NR4A1                           Nuclear receptor subfamily 4, group A, member 1                                               −1.86138      8.90E-05
  SYTL2                           Synaptotagmin-like 2                                                                          −1.85889      0.00135142
  ARL4C                           ADP-ribosylation factor-like 4C                                                               −1.85424      0.000286602
  AGAP1                           ArfGAP with GTPase domain, ankyrin repeat and PH domain 1                                     −1.80837      0.000287414
  SH2D2A                          SH2 domain containing 2A                                                                      −1.80828      0.000300214
  KLRK1                           Killer cell lectin-like receptor subfamily K, member 1                                        −1.78448      0.00102739
  RUNX3                           Runt-related transcription factor 3                                                           −1.77892      0.00013984
  KIR3DL3                         Killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 3             −1.70915      0.000885828
  PER1                            Period homolog 1 (*Drosophila*)                                                               −1.70146      0.000444082
  CHD2                            Chromodomain helicase DNA DNA-binding protein 2                                               −1.70091      0.000257214
  DTX3                            Deltex homolog 3 (*Drosophila*)                                                               −1.70068      0.000829046
  PRKCH                           Protein kinase C, eta                                                                         −1.68436      0.00106358
  FAM179A                         Family with sequence similarity 179, member A                                                 −1.68265      0.000135121
  MGAT4A                          Mannosyl (alpha-1,3-)-glycoprotein beta-1,4-*N*-acetylglucosaminyltransferase, isozyme A      −1.67906      0.000326335
  GBP5                            Guanylate binding protein 5                                                                   −1.67871      0.000452814
  MLC1                            Megalencephalic leukoencephalopathy with subcortical cysts 1                                  −1.66993      0.000433367
  ANKRD36                         Ankyrin repeat domain 36                                                                      −1.63932      0.000866547
  NFATC2                          Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2                     −1.63898      0.000941657
  SYNE2                           Spectrin repeat containing, nuclear envelope 2                                                −1.63663      1.19E-05
  ID2                             Inhibitor of DNA DNA-binding 2, dominant negative helix---loop---helix protein                −1.60803      1.67E-06
  KIF21A                          Kinesin family member 21A                                                                     −1.60799      0.00136965
  CTNNB1                          Catenin (cadherin-associated protein), beta 1, 88 kDa                                         −1.6076       4.09E-05
  TSEN54                          tRNA splicing endonuclease 54 homolog (*S. cerevisiae*)                                       −1.60547      0.000604728
  ZNF451                          Zinc finger protein 451                                                                       −1.60463      6.28E-06
  TSPAN5                          Tetraspanin 5                                                                                 −1.60208      0.00114212
  RASGEF1A                        RasGEF domain family, member 1A                                                               −1.60149      0.000447691
  TNIK                            TRAF2 and NCK interacting kinase                                                              −1.59894      2.50E-05
  CBLB                            Cas-Br-M (murine) ecotropic retroviral transforming sequence b                                −1.5979       0.000320734
  MLLT11                          Myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, *Drosophila*); translocate     −1.59317      0.000831119
  TAF9B                           TAF9B RNA polymerase II, TATA box binding protein (TBP)-associated factor, 31 kDa             −1.5885       0.000321819
  HNRNPL                          Heterogeneous nuclear ribonucleoprotein L                                                     −1.5871       3.77E-06
  SESN2                           Sestrin 2                                                                                     −1.57849      6.97E-05
  LOC100130872                    Hypothetical LOC100130872                                                                     −1.56568      1.48E-05
  SESN2                           Sestrin 2                                                                                     −1.56417      0.00050745
  CCL5                            Chemokine (C---C motif) ligand 5                                                              −1.56409      0.000430274
  PIK3R1                          Phosphoinositide-3-kinase, regulatory subunit 1 (alpha)                                       −1.56311      0.00143535
  TFDP2                           Transcription factor Dp-2 (E2F dimerization partner 2)                                        −1.55293      0.000804861
  PDE4B                           Phosphodiesterase 4B, cAMP-specific                                                           −1.55035      0.00085501
  RBM14                           RNA binding motif protein 14                                                                  −1.54638      2.35E-05
  FAM100B                         Family with sequence similarity 100, member B                                                 −1.53662      7.63E-05
  PDE4D                           Phosphodiesterase 4D, cAMP-specific                                                           −1.53463      0.000469774
  GRPEL1                          GrpE-like 1, mitochondrial (*E. coli*)                                                        −1.53133      1.23E-05
  ZNF507                          Zinc finger protein 507                                                                       −1.52977      0.000202111
  NUP153                          Nucleoporin 153 kDa                                                                           −1.52758      0.000367042
  FUS                             Fused in sarcoma                                                                              −1.52544      0.0010451
  PTTG1                           Pituitary tumor-transforming 1                                                                −1.52511      0.000818797
  WAC                             WW domain containing adaptor with coiled-coil                                                 −1.52328      0.000534293
  EIF1                            Eukaryotic translation initiation factor 1                                                    −1.52229      6.21E-06
  TSEN54                          tRNA splicing endonuclease 54 homolog (*S. cerevisiae*)                                       −1.50904      0.000620767
  MYLIP                           Myosin regulatory light chain interacting protein                                             −1.50894      3.24E-05
  CALU                            Calumenin                                                                                     −1.50768      0.000736822
  EHD4                            EH-domain containing 4                                                                        −1.50216      0.000209267
  ATP11B                          ATPase, class VI, type 11B                                                                    1.50127       0.000202173
  FKBP15                          FK506 binding protein 15, 133 kDa                                                             1.50442       0.000270622
  MOCS3                           Molybdenum cofactor synthesis 3                                                               1.5075        4.38E-06
  FAM13A                          Family with sequence similarity 13, member A                                                  1.50801       0.00135619
  CDC42EP3                        CDC42 effector protein (Rho GTPase binding) 3                                                 1.50849       2.59E-05
  DACH1                           Dachshund homolog 1 (*Drosophila*)                                                            1.51638       0.000969487
  HHEX                            Hematopoietically expressed homeobox                                                          1.51675       6.21E-05
  PDE7B                           Phosphodiesterase 7B                                                                          1.51869       2.37E-05
  OBFC2A                          Oligonucleotide/oligosaccharide-binding fold containing 2A                                    1.52002       0.000343088
  CR1                             Complement component (3b/4b) receptor 1 (Knops blood group)                                   1.52311       9.05E-05
  PHF23                           PHD finger protein 23                                                                         1.53301       3.41E-06
  ZNF780A                         Zinc finger protein 780A                                                                      1.53325       0.000505801
  GPR27                           G protein-coupled receptor 27                                                                 1.53487       0.0011538
  CDC42EP3                        CDC42 effector protein (Rho GTPase binding) 3                                                 1.53614       1.72E-05
  ADPRH                           ADP-ribosylarginine hydrolase                                                                 1.53673       0.000301124
  TLR4                            Toll-like receptor 4                                                                          1.54384       0.000155809
  TLR10                           Toll-like receptor 10                                                                         1.54391       0.000150659
  SIRPB2                          Signal-regulatory protein beta 2                                                              1.55351       9.39E-05
  FUBP1                           Far upstream element (FUSE) binding protein 1                                                 1.55437       3.43E-05
  NLRC4                           NLR family, CARD domain containing 4                                                          1.5579        0.0010619
  OBFC2A                          Oligonucleotide/oligosaccharide-binding fold containing 2A                                    1.55822       6.88E-05
  TRPS1                           Trichorhinophalangeal syndrome I                                                              1.56073       0.00117806
  CLIC4                           Chloride intracellular channel 4                                                              1.56137       0.00142631
  ANKRD57                         Ankyrin repeat domain 57                                                                      1.56891       0.000496592
  FOSL2                           FOS-like antigen 2                                                                            1.57091       0.00103799
  FBXO30                          F-box protein 30                                                                              1.57898       3.37E-05
  S1PR3                           Sphingosine-1-phosphate receptor 3                                                            1.57953       0.000766403
  MFAP3                           Microfibrillar-associated protein 3                                                           1.58049       8.30E-05
  CPD                             Carboxypeptidase D                                                                            1.58561       0.000270503
  RNF24                           Ring finger protein 24                                                                        1.5887        0.000779404
  PIGM                            Phosphatidylinositol glycan anchor biosynthesis, class M                                      1.58922       3.93E-06
  SAP30L                          SAP30-like                                                                                    1.599         3.48E-05
  SERPINI2                        Serpin peptidase inhibitor, clade I (pancpin), member 2                                       1.60236       0.000725023
  BACH1                           BTB and CNC homology 1, basic leucine zipper transcription factor 1                           1.60519       5.89E-06
  ZNF322B                         Zinc finger protein 322B                                                                      1.60589       0.000435523
  ZEB2                            Zinc finger E-box binding homeobox 2                                                          1.61326       0.0010863
  GPATCH2                         G patch domain containing 2                                                                   1.61607       0.000829918
  KCNE3                           Potassium voltage-gated channel, Isk-related family, member 3                                 1.62682       0.000871206
  ENTPD1                          Ectonucleoside triphosphate diphosphohydrolase 1                                              1.62899       0.000688504
  FAM114A1                        Family with sequence similarity 114, member A1                                                1.63805       0.000957221
  ZNF697                          Zinc finger protein 697                                                                       1.63815       0.000362559
  SIPA1L1                         Signal-induced proliferation-associated 1 1-like 1                                            1.63837       0.000200843
  MGST1                           Microsomal glutathione S-transferase 1                                                        1.63932       0.000155808
  CENPBD1                         CENPB DNA-binding domains containing 1                                                        1.63975       0.000598446
  LOC100505956                    Hypothetical LOC100505956                                                                     1.6413        0.00103297
  CTTNBP2NL                       CTTNBP2 N-terminal like                                                                       1.6428        0.00126079
  CLLU1                           Chronic lymphocytic leukemia up-regulated 1                                                   1.65206       0.000787124
  ST8SIA4                         ST8 alpha-*N*-acetyl-neuraminide alpha-2,8-sialyltransferase 4                                1.66224       0.000130372
  FAR2                            Fatty acyl CoA reductase 2                                                                    1.68735       5.72E-05
  DAPP1                           Dual adaptor of phosphotyrosine and 3-phosphoinositides                                       1.68966       0.000609128
  PLD1                            Phospholipase D1, phosphatidylcholine-specific                                                1.69193       0.000517971
  MGST1                           Microsomal glutathione S-transferase 1                                                        1.69246       0.00020858
  MGST1                           Microsomal glutathione S-transferase 1                                                        1.69458       7.19E-06
  DSC2                            Desmocollin 2                                                                                 1.69681       0.000254904
  GPATCH2                         G patch domain containing 2                                                                   1.70199       0.000112569
  ST6GALNAC3                      ST6 (alpha-*N*-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-*N*-acetylgalactosaminide alpha-2   1.70328       0.000428429
  FBN2                            Fibrillin 2                                                                                   1.721         0.000252441
  FCGR1B                          Fc fragment of IgG, high affinity Ib, receptor (CD64)                                         1.72442       0.000706171
  HP                              Haptoglobin                                                                                   1.72582       0.000718758
  FRAT2                           Frequently rearranged in advanced T-cell lymphomas 2                                          1.72608       0.000190515
  HHEX                            Hematopoietically expressed homeobox                                                          1.7329        4.10E-06
  P2RY13                          Purinergic receptor P2Y, G-protein coupled, 13                                                1.73405       0.000133887
  MGST1                           Microsomal glutathione S-transferase 1                                                        1.74784       7.56E-05
  LOC100506828                    Hypothetical LOC100506828                                                                     1.75228       7.44E-05
  TFEC                            Transcription factor EC                                                                       1.75494       0.000135064
  WLS                             Wntless homolog (*Drosophila*)                                                                1.76165       0.000227731
  FCGR1A///FCGR1C                 Fc fragment of IgG, high affinity Ia, receptor (CD64)///Fc fragment of IgG, high affinity     1.76282       0.00095328
  SGMS2                           Sphingomyelin synthase 2                                                                      1.76728       0.000618004
  ATP6V1A                         ATPase, H + transporting, lysosomal 70 kDa, V1 subunit A                                      1.77021       3.21E-05
  FPR2                            Formyl peptide receptor 2                                                                     1.77041       8.98E-05
  ADAM9                           ADAM metallopeptidase domain 9                                                                1.82176       2.72E-05
  TMEM49                          Transmembrane protein 49                                                                      1.8221        0.000516735
  WSB1                            WD repeat and SOCS box-containing 1                                                           1.82444       0.000178707
  NR3C1                           Promoter 1B of the GR                                                                         1.83029221    0.00019027
  ADAMTS5                         ADAM metallopeptidase with thrombospondin type 1 motif, 5                                     1.83321       0.000299013
  FPR2                            Formyl peptide receptor 2                                                                     1.85476       0.000499535
  EMP1                            Epithelial membrane protein 1                                                                 1.8738        0.000128519
  SPATA5L1                        Spermatogenesis associated 5-like 1                                                           1.87522       0.00102786
  PLA2G4A                         Phospholipase A2, group IVA (cytosolic, calcium-dependent)                                    1.87895       0.000196578
  TLR1                            Toll-like receptor 1                                                                          1.93858       2.14E-07
  LOC203274                       Hypothetical protein LOC203274                                                                1.94801       5.09E-05
  NFATC2                          Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2                     1.9776        5.93E-05
  FBXO30                          F-box protein 30                                                                              1.98992       0.000899931
  ATP6V1A                         ATPase, H + transporting, lysosomal 70 kDa, V1 subunit A                                      1.99          0.000810192
  CYP1B1                          Cytochrome P450, family 1, subfamily B, polypeptide 1                                         1.99311       9.37E-06
  STEAP4                          STEAP family member 4                                                                         2.01298       0.000150426
  IL8R1                           Interleukin 8 receptor 1                                                                      2.03E + 00    3.92893E-05
  IL2                             interleukin 2                                                                                 2.03419987    3.10905E-06
  FOLR3                           Folate receptor 3 (gamma)                                                                     2.05781       0.00017189
  FKBP15                          FK506 binding protein 15, 133 kDa                                                             2.094500914   4.30009E-05
  SLITRK4                         SLIT and NTRK-like family, member 4                                                           2.16832       6.47E-05
  ADAMTS5                         ADAM metallopeptidase with thrombospondin type 1 motif, 5                                     2.18224       0.00016302
  PTPRO                           Protein tyrosine phosphatase, receptor type, O                                                2.21369       0.000260765
  FAM198B                         Family with sequence similarity 198, member B                                                 2.22299       0.000661349
  FKBP506                         FKBP506 binding protein                                                                       2.223221099   1.90294E-06
  IFNGR1                          Interferon gamma receptor 1                                                                   2.51823       0.000195788
  TLR7                            Toll-like receptor 7                                                                          2.59205       0.00115974
  RIN2                            Ras and Rab interactor 2                                                                      2.62017       0.000313438
  TLR8                            Toll-like receptor 8                                                                          2.62471       0.00112645
  TLR4                            Toll-like receptor 4                                                                          2.66149       0.000182505
  MIR21                           MicroRNA 21                                                                                   2.68409       0.000265287
  CYP1B1                          Cytochrome P450, family 1, subfamily B, polypeptide 1                                         2.83233       0.000146054
  PDK4                            Pyruvate dehydrogenase kinase, isozyme 4                                                      2.99062       7.43E-07
  PDK4                            Pyruvate dehydrogenase kinase, isozyme 4                                                      3.1238        0.000118651

###### 

**Down-regulated gene expression (top 50)**.

  Gene symbol                     Gene title                                                                              Fold-change   *p*-Value
  ------------------------------- --------------------------------------------------------------------------------------- ------------- ------------
  CCL4                            Chemokine (C--C motif) ligand 4                                                         −3.39         0.0004
  EGR3                            Early growth response 3                                                                 −3.333        4.37E-05
  IL1B                            Interleukin 1, beta                                                                     −3.193        0.00054
  TIGIT                           T cell immunoreceptor with Ig and ITIM domains                                          −2.999        0.00012
  CD96                            CD96 molecule                                                                           −2.999        0.00059
  CCL3///CCL3L1///CCL3L3          Chemokine (C--C motif) ligand 3///chemokine (C--C motif) ligand 3-like 1///chemokine    −2.998        1.32E-05
  CCL5                            Chemokine (C--C motif) ligand 5                                                         −2.966        0.00088
  TNF                             Tumor necrosis factor                                                                   −2.906        0.00054
  DUSP1                           Dual specificity phosphatase 1                                                          −2.897        1.73E-05
  GATA3                           GATA binding protein 3                                                                  −2.889        0.00085
  PTGS2                           Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)   −2.862        0.00012
  BZRAP1                          Benzodiazepine receptor (peripheral) associated protein 1                               −2.846        0.00043
  KIR3DL1///KIR3DL2///LOC727787   Killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 1///k   −2.796        0.00112
  IL18R1                          Interleukin 18 receptor 1                                                               −2.792        0.00131
  NFATC2                          Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2               −2.776        0.00047
  IFITM1                          Interferon-induced transmembrane protein 1 (9--27)                                      −2.676        0.0008
  IL6                             Interleukin 6 (interferon, beta 2)                                                      −2.666        0.00017
  IFITM1                          Interferon-induced transmembrane protein 1 (9--27)                                      −2.591        0.0012
  GLCCI1                          Glucocorticoid induced transcript 1                                                     −2.579        0.00086
  PER1                            Period homolog 1 (*Drosophila*)                                                         −2.345        0.00017
  TARP///TRGC2                    TCR gamma alternate reading frame protein///T cell receptor gamma constant 2            −2.313        0.00086
  TARP                            TCR gamma alternate reading frame protein                                               −2.243        0.00123683
  TP53INP2                        Tumor protein p53 inducible nuclear protein 2                                           −2.232        2.18E-04
  CDC14A                          CDC14 cell division cycle 14 homolog A (*S. cerevisiae*)                                −2.223        0.00055
  ZNF831                          Zinc finger protein 831                                                                 −2.212        0.00094
  BCL10                           B-cell CLL/lymphoma 10                                                                  −2.196        1.92E-04
  TARP///TRGC2                    TCR gamma alternate reading frame protein///T cell receptor gamma constant 2            −2.186        0.00138
  TARP///TRGC2                    TCR gamma alternate reading frame protein///T cell receptor gamma constant 2            −2.172        0.00137
  STAT3                           Signal transducer and activator of transcription 3 (acute-phase response factor)        −2.171        2.79E-05
  IL13                            Interleukin 13                                                                          −2.1          0.00045
  ZNF831                          Zinc finger protein 831                                                                 −2.074        0.001
  GZMB                            Granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1)            −2.073        0.00011
  KLF12                           Kruppel-like factor 12                                                                  −2.067        0.00047
  SPON2                           Spondin 2, extracellular matrix protein                                                 −2.063        0.00056
  MBNL2                           Muscleblind-like 2 (*Drosophila*)                                                       −2.062        0.00015
  KRAS                            v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog                                    −2.05         0.00083
  CRA                             Complement factor C4                                                                    −2.048        7.09E-05
  FCAR                            Fc fragment of IgA, receptor for                                                        −2.036        1.89E-04
  NCL                             Nucleolin                                                                               −2.031        4.39E-07
  IFRD1                           Interferon-related developmental regulator 1                                            −2.025        7.16E-06
  S1PR5                           Sphingosine-1-phosphate receptor 5                                                      −2.00         0.00088
  NAP1L5                          Nucleosome assembly protein 1-like 5                                                    −1.983        0.00103
  FGFBP2                          Fibroblast growth factor binding protein 2                                              −1.959        0.00098
  TRD                             T cell receptor delta locus                                                             −1.953        0.00111
  PYHIN1                          Pyrin and HIN domain family, member 1                                                   −1.935        0.00099
  GFI1                            Growth factor independent 1 transcription repressor                                     −1.932        0.00076
  GZMM                            Granzyme M (lymphocyte met-ase 1)                                                       −1.931        0.00085
  TRD                             T cell receptor delta locus                                                             −1.921        0.00112
  TSC22D3                         TSC22 domain family, member 3                                                           −1.911        2.28E-06
  KLRB1                           Killer cell lectin-like receptor subfamily B, member 1                                  −1.91         0.00137

###### 

**Up-regulated gene expression (top 50)**.

  Gene symbol       Gene title                                                                                    Fold-change   *p*-Value
  ----------------- --------------------------------------------------------------------------------------------- ------------- -----------
  PDK4              Pyruvate dehydrogenase kinase, isozyme 4                                                      3.1238        0.00012
  CYP1B1            Cytochrome P450, family 1, subfamily B, polypeptide 1                                         2.83233       0.00015
  MIR21             MicroRNA 21                                                                                   2.68409       0.00027
  TLR4              Toll-like receptor 4                                                                          2.66149       0.00018
  TLR8              Toll-like receptor 8                                                                          2.62471       0.00113
  RIN2              Ras and Rab interactor 2                                                                      2.62017       0.00031
  TLR7              Toll-like receptor 7                                                                          2.59205       0.00116
  IFNGR1            Interferon gamma receptor 1                                                                   2.51823       0.0002
  FKBP506           FKBP506 binding protein                                                                       2.22322       1.90E-06
  FAM198B           Family with sequence similarity 198, member B                                                 2.22299       0.00066
  PTPRO             Protein tyrosine phosphatase, receptor type, O                                                2.21369       0.00026
  ADAMTS5           ADAM metallopeptidase with thrombospondin type 1 motif, 5                                     2.18224       0.00016
  SLITRK4           SLIT and NTRK-like family, member 4                                                           2.16832       6.47E-05
  FKBP15            FK506 binding protein 15, 133 kDa                                                             2.0945        4.30E-05
  FOLR3             Folate receptor 3 (gamma)                                                                     2.05781       0.00017
  IL2               Interleukin 2                                                                                 2.0342        3.10E-06
  IL8R1             Interleukin 8 receptor 1                                                                      2.03E + 00    3.90E-05
  STEAP4            STEAP family member 4                                                                         2.01298       0.00015
  ATP6V1A           ATPase, H+ transporting, lysosomal 70 kDa, V1 subunit A                                       1.99          0.00081
  FBXO30            F-box protein 30                                                                              1.98992       0.0009
  NFATC2            Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 2                     1.9776        5.90E-05
  LOC203274         Hypothetical protein LOC203274                                                                1.94801       5.09E-05
  TLR1              Toll-like receptor 1                                                                          1.93858       2.14E-07
  PLA2G4A           Phospholipase A2, group IVA (cytosolic, calcium-dependent)                                    1.87895       0.0002
  SPATA5L1          Spermatogenesis associated 5-like 1                                                           1.87522       0.00103
  EMP1              Epithelial membrane protein 1                                                                 1.8738        0.00013
  FPR2              Formyl peptide receptor 2                                                                     1.85476       0.0005
  ADAMTS5           ADAM metallopeptidase with thrombospondin type 1 motif, 5                                     1.83321       0.0003
  NR3C1             Promoter 1B of the GR                                                                         1.83029       0.00019
  WSB1              WD repeat and SOCS box-containing 1                                                           1.82444       0.00018
  TMEM49            Transmembrane protein 49                                                                      1.8221        0.00052
  ADAM9             ADAM metallopeptidase domain 9                                                                1.82176       2.72E-05
  FPR2              Formyl peptide receptor 2                                                                     1.77041       8.98E-05
  ATP6V1A           ATPase, H+ transporting, lysosomal 70 kDa, V1 subunit A                                       1.77021       3.21E-05
  SGMS2             Sphingomyelin synthase 2                                                                      1.76728       0.00062
  FCGR1A///FCGR1C   Fc fragment of IgG, high affinity Ia, receptor (CD64)///Fc fragment of IgG, high affinity     1.76282       0.00095
  WLS               Wntless homolog (*Drosophila*)                                                                1.76165       0.00023
  TFEC              Transcription factor EC                                                                       1.75494       0.00014
  LOC100506828      Hypothetical LOC100506828                                                                     1.75228       7.44E-05
  MGST1             Microsomal glutathione S-transferase 1                                                        1.74784       7.56E-05
  P2RY13            Purinergic receptor P2Y, G-protein coupled, 13                                                1.73405       0.00013
  HHEX              Hematopoietically expressed homeobox                                                          1.7329        4.10E-06
  FRAT2             Frequently rearranged in advanced T-cell lymphomas 2                                          1.72608       0.00019
  HP                Haptoglobin                                                                                   1.72582       0.00072
  FCGR1B            Fc fragment of IgG, high affinity Ib, receptor (CD64)                                         1.72442       0.00071
  FBN2              Fibrillin 2                                                                                   1.721         0.00025
  ST6GALNAC3        ST6 (alpha-*N*-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-*N*-acetylgalactosaminide alpha-2   1.70328       0.00043
  GPATCH2           G patch domain containing 2                                                                   1.70199       0.00011
  DSC2              Desmocollin 2                                                                                 1.69681       0.00025
  MGST1             Microsomal glutathione S-transferase 1                                                        1.69458       7.19E-06

Expression of inflammatory cytokines were substantially reduced in the improved sleep group, including interleukin 1 beta (IL-1β), interleukin 6 (IL-6), interleukin 8 (IL-8), and interleukin 13 (IL-13), with fold changes ranging from −3.19 to −2.10. We also report significant reductions in chemokine genes including chemokine (C--C motif) ligand 4 (CCL4), which was the most substantially reduced gene, with a fold change of −3.39, as well as chemokine (C--C motif) ligand 3 (CCL3), and chemokine (C--C motif) ligand 5 (CCL5), with fold-changes of −3.00 and −2.97, respectively, in the improved sleep group.

Genes with increases in expression in the improved sleep group were predominately inflammatory regulatory genes including toll-like receptors 4 and 8 (TLR4 and TLR8), with a 2.66- and 2.62-fold change, respectively, as well as toll-like receptors 7 and 1 (TLR7 and TLR1), with fold changes of 2.6 and 1.9, respectively. Stress-related genes of cytochrome P450, family 1, subfamily B, polypeptide 1 (CYP1B1), FKBP506 binding protein (FKBP506), and FK506 binding protein 15, 133 kDa (FKBP15) exhibited fold changes \>2.0. The pyruvate dehydrogenase kinase, isozyme 4 genes had the greatest increase in expression, with a fold change of 3.12.

The IPA report shows conical pathways were altered and related to improved sleep. The pathways include the inflammatory response, infectious disease, inflammatory disease, and organismal injury and abnormalities. There were six significant gene-networks identified, the scores of which are reported in Table [6](#T6){ref-type="table"}. Networks 1 and 2 are provided in Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}, and the remaining Figures [S1](#SM1){ref-type="supplementary-material"}--[S4](#SM4){ref-type="supplementary-material"} are provided in the Supplementary Material. With the exception of the third IPA network, the other five contained genes above a fold change of 2 in the networks reported. Network 1 includes genes related to cellular development and tissue disorders, and has a score of 29. In this network, there are three main hubs: Catenin (cadherin-associated protein), beta 1, 88 kDa (CTNNβ1), toll-like receptors (TLR), and interleukin 2 (IL-2), as well as minor hubs of ubiquitin (UBC), polyketide synthase (PKS), and nuclear factor of activated T-cells 2 (NFATC2). Network 2 has a score of 23, and includes genes related to cancer, and tissue and developmental disorders. This network has a primary hub of UBC, which is related to an increase in expression of FKBP15 and ATPase, H+ transporting, lysosomal 70 kDa, and V1 subunit A (ATP6V1A), and reductions in the expression of TSEN54 tRNA splicing endonuclease and megalencephalic leukoencephalopathy with subcortical cysts 1.

###### 

**IPA network scores**.

  Networks   Score
  ---------- -------
  1          29
  2          14
  3          14
  4          14
  5          13
  6          14

*This table lists the scores of the six networks (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}; Figures [S1](#SM1){ref-type="supplementary-material"}--[S4](#SM4){ref-type="supplementary-material"} in Supplementary Material) as reported by ingenuity pathway analysis (IPA). Following the compilation of networks, based on the interconnectivity of each gene, IPA finalizes the report by ranking each network based on a calculation of *p*-scores \[*p*-score = −log~10~(*p*-value)\]. This score accounts for the number of genes versus the size of the network to estimate how valid this network is to the original list of genes. This allows for the networks to be prioritized as seen in Table [6](#T6){ref-type="table"}, where a score above 20 is seen as more significant*.

![**This network shows genes related to cellular development and connective tissue**. Generated molecular network based on differential expression in the improved sleep group from baseline to follow-up using ingenuity knowledge database. Coloring is based on the expression values of the genes (fold changes shown): down-regulation in green and up-regulation in red. Genes with no coloring are added from ingenuity knowledge database. Direct and indirect relationships are shown by solid and dashed lines, respectively. The arrow indicates specific directionality of interactions. Genes with an asterisk indicate that multiple identifiers (probesets) map to the gene in the molecular network. Reprinted with permission from QIAGEN's Ingenuity^®^ Pathway Analysis (IPA^®^) (<http://www.ingenuity.com/>).](fpsyt-06-00059-g001){#F1}

![**This network shows genes related to developmental disorders, as reported by IPA**. Reprinted with permission from QIAGEN's Ingenuity^®^ Pathway Analysis (IPA^®^) (<http://www.ingenuity.com/>).](fpsyt-06-00059-g002){#F2}

Discussion {#S4}
==========

The primary aim of the current study is to examine the relationship between changes in self-reported sleep quality and changes in expression of inflammatory genes and symptoms of depression and PTSD following 3 months of sleep treatment in military personnel with insomnia and comorbid psychiatric disorders. At post-treatment, participants with improved sleep have significantly reduced depression symptoms and changes in gene expression, which most notably reflect reductions in inflammatory cytokine genes. These novel findings provide unique insights into our previous findings, which indicated improved sleep quality is associated with reductions in concentrations of CRP and improvements in health-related quality of life in military personnel ([@B23]). These results suggest that sleep-focused treatments effectively reduce inflammatory gene activity, and may attenuate the risk for inflammatory-related morbidity in this population.

Specifically, we report that gene activity is reduced in 113 genes following improved sleep, including significant reductions in the expression of the following inflammatory cytokine genes: CCL4, IL-1β, tumor necrosis factor (TNF), IL-6, and IL-13 (Table [4](#T4){ref-type="table"}). Elevated concentrations of IL-6 have been associated with symptoms of insomnia, PTSD, and depression ([@B22], [@B35]). The reduction in IL-6 secretion has significant ramifications as IL-6 has a pertinent role in the inflammatory response, including initiation of the acute-phase response and increasing metabolic risks as well as vascular plaque formation ([@B36]). Peripherally, IL-6 activates the production of inflammatory cytokines by initiating intracellular signaling with TLR ([@B37]). IL-6 is linked to substantial morbidity risks through arterial plaque formation, which can lead to cardiovascular disease and risks, high BMI, chronic pain, and an elevated risk for diabetes ([@B38]--[@B42]). Therefore, our findings suggest that improved sleep quality plays an important role in decreasing inflammation through gene-expression networks, which may also have a health-promoting role over time.

IL-6 also crosses the blood--brain barrier and contributes to central inflammation, and higher activity can contribute to mood alterations including symptoms of depression and anxiety ([@B36]). Here, we report depression symptoms decrease following improved sleep, and there is a trend for decreases in PTSD symptoms. Prior studies link inflammation to the onset of depressive symptoms, suggesting a complex bi-directional relationship that contributes to mental well-being ([@B43], [@B44]). Higher concentrations of IL-6 as well as increased gene-activity are established bio-markers for depression ([@B45]), yet, less is known about the inflammatory mechanisms that result from the interaction of insomnia and depression, and the resolution of symptoms. Previously, we reported that depression and insomnia in military personnel are associated with higher concentrations of CRP ([@B23]), and that improved sleep reduces inflammation ([@B24]). Here, we extend these findings by linking gene expression to sleep improvement and reduction in depression symptoms. In addition, we report a significant reduction in the expression of the CCL4 gene, which was reduced by −3.39 fold in the improved sleep group. CCL4 is an initiator of the inflammatory processes, suggesting inflammatory pathways are reduced in activity following sleep restoration and reduction in depression symptoms. Greater CCL4 activity is linked to major depressive disorder in both adolescents and adults ([@B46], [@B47]); however, it is not clear if the activity of this gene or other inflammatory initiating genes change following sleep improvement and mood change. Therefore, our findings of reductions in CCL4 following sleep improvement are novel and provide some initial insights into complex relationships among genes that regulate inflammation, sleep, and mood.

The current study also found a significant increase in the expression of 104 genes, with most being related to the regulation of inflammatory activity (Table [5](#T5){ref-type="table"}). Of these up-regulated genes, the highest fold change is in pyruvate dehydrogenase kinase, isozyme 4 (PDK4), with a 3.12-fold change in the improved sleep group. This gene is of interest as it is located in the matrix of the mitochondria. PDK4 reduces the conversion of pyruvate, which is produced from the oxidation of glucose and amino acids, to acetyl-CoA. It also contributes to the regulation of glucose metabolism and has ramifications for overall health and morbidity. PDK4 has not been previously linked to sleep disturbance or mood. Here, we report that this gene increases expression in the context of reduced expression of genes that influence inflammation and contribute significantly to metabolic risk. Exercise alters the activity of PDK4, which relates to reductions in IL-6 activity, suggesting that PDK4 is involved in metabolic processes that are important to maintaining health ([@B48]). PDK4 is also implicated in the maintenance of body weight during periods of fasting, as it is required to maximize glucose metabolism; however, when animals are exposed to high-caloric diets that are unrestricted, PDK4 increases in expression ([@B49]). Therefore, PDK4 has complex relations to comorbid conditions of type 2 diabetes, cardiovascular disease, and other conditions that are common in military personnel and impact their morbidity. For these reasons, additional studies are needed to determine how this gene relates to sleep and mood, as well as morbidity risk in future studies.

In this study, we report two main gene-networks that are implicated in sleep improvement. The first involves the key regulator CTNNβ1, a gene that relates to the activity of both IL-2 and TLR4, as well as ubiquitin genes (Figure [1](#F1){ref-type="fig"}). The CTNNβ1 is most often implicated in vulnerability to and recovery from cancer ([@B50]--[@B52]); however, the role of this gene in sleep quality has not yet been determined. This gene encodes for the β-catenin protein, which regulates cell development and adhesion between cells, in turn creating and preserving epithelial cell layers, which is related to inflammatory gene activity. Activation of the Wnt signaling pathway, which is a pertinent system for cell-to-cell communications and which becomes activated during inflammatory responses, is essential in maintaining immune function system balance between inflammatory and anti-inflammatory activities. The result is increased concentrations of the protein that is coded by CTNNβ1 gene, which is linked to both increases in symptoms of depression and anxiety in clinical samples ([@B53]). Of importance, we also report an increase in IL-2 gene expression, which is a primary anti-inflammatory cytokine and is important for regulating inflammatory cytokine activity including IL-1β, IL-6, and TNF. Therefore, an increase in the expression of the IL-2 gene in conjunction with other inflammatory regulators suggests that regulatory gene networks are altered following sleep restoration, and likely contribute to our previous finding of reductions in CRP following improved sleep ([@B23]). Thus, these gene-expression findings together suggest that there is an alteration in the activity of the acute-phase response, which is responsible for the initiation of CRP production. Although we did not find that CRP significantly reduced in activity, our finding of reductions in the activity of these precursor genes that are more easily reduced in activity suggests that changes in CRP gene-activity may require more time to observe. Although our findings provide some key insights into the role of inflammation following sleep change, much less is known about the long-term impact of sleep disturbance on morbidity risks in military personnel and veterans.

We also report that TLRs, and specifically TLR4 gene expression is increased in the improved sleep group, and is also a key gene-network regulator of inflammatory activities. TLR4 recognizes pathogen-associated molecular patterns that are expressed by infectious agents, and mediate the production of cytokines necessary for the development of effective immunity, thereby regulating inflammatory cytokine activities following a stimulus. TLR4 has been linked to repeated hypoxia events in a pre-clinical model, suggesting that acute sleep deprivation may increase TLR activity ([@B54]). Our findings of an increase in TLR4 following improved sleep in conjunction with reduced activities of inflammatory cytokines suggests that the activities of TLR4 are impacted, contributing to a restoration of inflammatory immune cell function. Since UBC is tightly related to TLR4 in our gene-network, it may be that the protein-interaction properties of UBC that results in lessened gene activity may contribute to this immune profile in gene expression. It may also be that different molecular regulation mechanisms, including DNA methylation or other gene-silencing processes, are occurring. Nonetheless, the presence of TLR4 in this sample suggests it aided in the reduction of inflammation, as well as interacting with other pathways within the improved sleep group.

Our findings also implicated the protein UBC pathway in gene expression following improved sleep (Figure [2](#F2){ref-type="fig"}). Protein UBC is required for the removal of oxidized or misfolded proteins that are a consequence of neuronal activity that occurs during waking hours; it also alters the location of the protein in the cell or prevents protein interactions. In pre-clinical models, substantial sleep deprivation results in an accumulation of these bi-products within neurons, and subsequent neuronal damage ([@B55]). Accumulation of over-oxidized proteins is linked to cognitive impairments in insomnia patients ([@B56]). Therefore, there is an important role for ubiquitin in sleep regulation, which has been recently described in pre-clinical models including *Drosophila*, linking a knockdown of the E3 ubiquitin ligase Cul3 to sleep disruption ([@B57]). Reductions in the activity of E3 ubiquitin ligase Cul3 in neurons resulted in the insomniac phenotype ([@B55]). In mice with a spontaneous deletion in the ubiquitin carboxyl-terminal hydrolase L1 gene, there was a lower number of orexin A-immunoreactive neurons in the lateral hypothalamus and greater disruption in circadian rhythm compared to wild-type mice ([@B58]). Thus, our findings, within the context of previous studies, suggest that UBC genes are key mediators of sleep-related gene-activity changes.

Our findings have clinical relevance, as previous studies report that insomnia tends to precede depression and PTSD and that treatment of sleep disturbances decreases disease severity ([@B59]). Second, because of the stigma associated with mental illness, military personnel are more likely to seek treatment for sleep disturbances than for PTSD ([@B14]). Treatment for depression and PTSD symptoms results in substantial financial cost that may be mitigated by providing sleep interventions. In support of this, a comprehensive study undertaken by the RAND corporation estimates that treatment for either major depression or PTSD costs between \$5,000 and \$15,000 for each military personnel treated over 1 year ([@B60]). Lastly, our finding that even short-term improvement in sleep has a significant impact on inflammatory gene-activity, as well as reductions in depression symptoms, suggests that early assessment and treatment for insomnia following deployment is warranted, especially in military personnel with mood declines.

While our study has strengths, including a validated sleep measure, evaluation of comorbid symptoms, and a longitudinal design, there are some notable limitations. These include a relatively small sample of military personnel recruited from the same treatment facility. In addition, our sample primarily consisted of male participants and therefore cannot be generalized to women. Although we used validated questionnaires to determine PTSD and depression symptoms, these instruments did not provide a definitive clinical diagnosis. Lastly, other variations such as prescribed medications used by patients prior to the study and dose of treatment, including the number of treatment sessions attended and other interventional methods could have further impact on gene expression; however, the aim of this study is to focus on symptom and gene-expression changes, not to validate a standard of care treatment. In the future, a larger sample size and better estimate of treatment adherence and fidelity among participants are needed to confirm these findings.

Our novel findings suggest improved sleep quality has a biological correlate as well as a correlation with psychological symptoms. Less is known regarding the long-term impact of sleep disturbance on morbidity risks in military personnel and veterans; however, our findings suggest that improving sleep quality reduces inflammatory risks and psychiatric symptom severity. Therefore, our findings provide fundamental insights related to the connections between sleep improvement and gene expression, including inflammatory gene-activity, which may be used to reduce morbidity risks in military personnel following deployment. Improving assessment and treatment of sleep disturbance in this at-risk group may provide a novel health promotion opportunity.
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**This network shows genes related to cell-mediated immune responses, as reported by IPA**. Reprinted with permission from QIAGEN's Ingenuity^®^ Pathway Analysis (IPA^®^) (<http://www.ingenuity.com/>).
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**This network shows genes related to connective tissue disorders, as reported by IPA**. Reprinted with permission from QIAGEN's Ingenuity^®^ Pathway Analysis (IPA^®^) (<http://www.ingenuity.com/>).
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**This network shows genes related to cellular function and maintenance and cellular development, as reported by IPA**. Reprinted with permission from QIAGEN's Ingenuity^®^ Pathway Analysis (IPA^®^) (<http://www.ingenuity.com/>).
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**This network shows genes related to organismal injury and abnormalities, as reported by IPA**. Reprinted with permission from QIAGEN's Ingenuity^®^ Pathway Analysis (IPA^®^) (<http://www.ingenuity.com/>).
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